Doraya (855362)

  https://cordis.europa.eu/project/id/855362

  Horizon 2020 (2014-2020)

  Doraya is an innovative catheter device for treating patients resistant to diuretics with Acute Heart Failure (AHF) condition.

  SME instrument (EIC-SMEInst-2018-2020)

  mortality  ·  cardiology

  2019-01-01 Start Date (YY-MM-DD)

  2019-04-30 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includes difficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around the world (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between 20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3 decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population will increase the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the key treatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics. The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency to relieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients, including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bn in 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total Chronic Heart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistant to diuretics, this represents a huge unmet market that Doraya can service.

  Complicit Organisations

1 Israeli organisation participates in Doraya.